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Purpose: We conducted post-hoc analyses of OA patients in the
Hyalgan® Use in Painful Shoulder (HUPS) Study to investigate
application of the OMERACT-OARSI treatment response criteria
to these findings, reported previously.
To our knowledge this is the first application of these criteria to
hyaluronan use in patients with pain associated with OA of the
shoulder.
Methods: We investigated application of Proposition D of the
OMERACT-OARSI criteria to both pain on movement (100-mm
VAS, n=286) and night pain (n=285) in OA patients from the
HUPS ITT population. Patients who received either 3 or 5 weekly
injections of sodium hyaluronate (HYL) were pooled for this anal-
ysis and compared to those who received 5 weekly injections of
phosphate-buffered saline (PBS). For both of these pain param-
eters, the Shoulder Rating Questionnaire (SRQ) daily activities
scale served as the function domain, and SRQ VAS served as
the global assessment domain. Both the 2- and 3-level responder
definitions were used.
Results: For VAS pain on movement (HYL, n=192; PBS, n=94),
HYL patients demonstrated greater treatment response than
PBS in both the 2-level (131/192, 68% vs. 50/94, 53%) and 3-
level (high responder, 100/192 [52%] vs. 32/94 [34%]; moderate
responder, 31/192 [16%] vs. 18/94 [19%]) responder definitions.
These results were consistent for VAS night pain in both the
2-level and 3-level responder definitions.
Conclusions: Our application of the OMERACT-OARSI treat-
ment responder criteria to the HUPS study further support the
effectiveness of HYL in patients suffering from pain on movement
and/or night pain associated with OA of the shoulder.
P315
PHARMACOLOGICAL TREATMENT OF KNEE
OSTEOARTHRITIS IN PRIMARY CARE
M. Acasuso-Diaz1, J. Vidal-Lorenzo1, F. Galdo2
1SAP S Jose Sergas, La Coruña, Spain, 2H.U. Juan Canalejo,
La Coruña, Spain
Purpose: To determine the main drugs prescribed by physi-
cians in an urban Primary Care center in La Coruña (Spain) for
treatment of patients with knee osteoarthritis.
Methods: Clinical charts of patients diagnosed with knee os-
teoarthritis and attended throughout 2004 were reviewed, and
patients meeting ACR criteria were selected. A total of 350
patients were diagnosed with knee osteoarthritis, out of which
207, 153 (74%) women and 54 (26%) men, could be evaluated.
40 patients (19.3%) showed right knee involvement whereas
34 (16.4%) showed left knee involvement. There was bilateral
involvement in 133 patients (64.25%).
Results: Three drug groups were evaluated: non-steroid anti-
inflammatories (NSAIDS), paracetamol, and symptomatic slow-
acting drugs (SYSADOA), considering as such glucosamine sul-
phate, chondroitin sulphate and diacerein.
58 patients (29%) were using drugs belonging to the three
groups; 45 (22.5%) were using NSAIDS and paracetamol; 30
(15%) were using NSAIDS and SYSADOA, 28 (14%) were
just using NSAIDS; 15 (7.5%) were using paracetamol and
SYSADOA; 15 (7.5%) only paracetamol and 9 (4.5%) only
SYSADOA. 104 (50.24%) patients were using topical pharmaco-
logical treatment.
Conclusions: Most of the patients - 103 (51.5%) - are treated
in our center with a combination of a SYSADOA and one or two
fast-acting drugs (either NSAIDS or paracetamol, or both). As
monotherapy, NSAIDS were used the most.
Topical treatment was used on a regular basis by half of the
patients.
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Purpose: To compare the efficacy, safety and tolerability of oral
dexibuprofen and ibuprofen in the management of adult Indian
patients with osteoarthritis of knee.
Methods: A prospective, open-label, two-group, comparative,
multicentric study was undertaken in 238 adult Indian pa-
tients,(30 to 70 years) with a clinical diagnosis of osteoarthri-
tis of the knee. The study was conducted in 5 centers across
the country after approval by the respective Institutional boards
amnd obtaining written informed consent from all patients. Pa-
tients fulfilling the inclusion and exclusion criteria were treated
with either Dexibuprofen 400mg- or Ibuprofen 600mg- both one
tablet three times a day for 4 weeks as per the randomization
schedule. The primary efficacy variable of the present study were
improvements in the Western Ontario and McMasters (WOMAC)
individual osteoarthritis (OA) indices and Composite Index (for
pain, stiffness and physical function) and the Visual Analog
Scale (VAS) scores (for pain). Secondary efficacy variable was
improvement in Patient’s and Physician’s global assessment of
efficacy of therapy. General clinical safety was monitored by
the incidence of treatment-emergent adverse events, physical
examination, assessments of vital signs and routine laboratory
tests.
Results: A total 225 (113 in Dexibuprofen and 112 patients in
ibuprofen group) patients completed the study were included in
the analysis while 13 patients (5 in dexibuprofen group and 8 in
inbuprofen group) were lost to follow-up and considered as drop-
outs. Both the drugs provided sustained relief of osteoarthritic
symptoms compared to baseline. There was a reduction of 89.9%
in mean pain score (WOMAC index) in the Dexibuprofen group
which was slightly more than 86.1% observed in the Ibuprofen
after 4 weeks of treatment. A significant reduction of 86.2% was
observed in the mean VAS pain score in Dexibuprofen group
which was significantly greater (p<0.05) as compared to 76.2%
observed in the Ibuprofen group at the end of the 4th week.
Therapy with dexibuprofen showed greater efficacy with regard
to reducing mean scores of stiffness, physical function, VAS pain
scores and mean total WOMAC Index scores as compared to
therapy with racemic Ibuprofen. According to both the investi-
gators’ and patients’ global assessment of efficacy 68.1% and
69.0% of total cases respectively treated with Dexibuprofen rated
efficacy as good to very good which was greater as compared
to 51.7%to 58.1% respectively reported in the Ibuprofen group.
Dexibuprofen was better tolerated by patients as compared to
therapy with racemic ibuprofen in this study. Lesser number of
patients treated with dexibuprofen (19.5%) reported mild to mod-
